Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.32 |
| ▸ | RGS12 | O14924 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20384698 | 1.00 | LMNA (0.37) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL109627 | 1.00 | LMNA (0.37) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30767122 | 0.99 | LMNA (0.36) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL10340552 | 0.92 | LMNA (0.34) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL17072479 | 0.90 | LMNA (0.33) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL15752290 | 0.89 | LMNA (0.33) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL29351145 | 0.89 | LMNA (0.38) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL321113 | 0.89 | LMNA (0.38) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL159766 | 0.89 | SMN1; SMN2 (0.39) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 | |
| SCHEMBL8610607 | 0.89 | LMNA (0.38) | LMNASMN1; SMN2HPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151464-A1 | ALPHA-PARTICLE RADIONUCLIDE-ANTIBODY CONJUGATES FOR TREATMENT OF SOLID TUMORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4347661-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | ImmunoGen, Inc. (US) | 2024-04-10 | — | — | EP | claimed |
| WO-2022256507-A1 | TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA | IMMUNOGEN, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| EP-4746899-A1 | TREATMENT OF CANCER PATIENTS WITH TUMOR INFILTRATING LYMPHOCYTE THERAPIES IN COMBINATION WITH TROP-2 TARGETING ADC | Iovance Biotherapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4642491-A1 | METHOD FOR GLYCOPROTEIN MODIFICATION | Honeybear Biosciences Inc. (TW) | 2025-11-05 | — | — | EP | disclosed |
| EP-4642488-A1 | ANTIBODY DRUG CONJUGATES | Yale University (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | Bicyclerd Limited (GB) | 2025-08-14 | — | — | US | disclosed |
| EP-4547284-A1 | ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES, COMPOSITIONS COMPRISING ANTI-ROR1 ANTIBODIES OR ANTIBODY CONJUGATES, AND METHODS OF MAKING AND USING ANTI-ROR1 ANTIBODIES AND ANTIBODY CONJUGATES | Sutro Biopharma, Inc. (US) | 2025-05-07 | — | — | EP | disclosed |
| EP-4531927-A1 | DOSAGE REGIMEN OF AN ANTI-CDH6 ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025048683-A1 | METHOD FOR DETECTION AND QUANTIFICATION OF CELL FREE DNA IN BIOLOGICAL SAMPLE | SANTERSUS AG (CH) | 2025-03-06 | — | — | WO | disclosed |
| EP-4514857-A2 | ANTI-NUCLEOPHOSMIN 1 ANTIBODY AND ANTIBODY CONJUGATE COMBINATION THERAPIES | The Children's Medical Center Corporation (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2022136555-A1 | IMPROVED CD30 TARGETING ANTIBODY DRUG CONJUGATES AND USES THEREOF | LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE) | 2022-06-30 | — | — | WO | disclosed |
| EP-4017532-A1 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | Children's Medical Center Corporation (US) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022103983-A9 | FLUORENYLMETHYLOXYCARBONYL AND FLUORENYLMETHYLAMINOCARBONYL COMPOUNDS, PROTEIN CONJUGATES THEREOF, AND METHODS FOR THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022112942-A2 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022103983-A2 | FLUORENYLMETHYLOXYCARBONYL AND FLUORENYLMETHYLAMINOCARBONYL COMPOUNDS, PROTEIN CONJUGATES THEREOF, AND METHODS FOR THEIR USE | SUTRO BIOPHARMA, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| EP-3986468-A1 | ANTIB0DY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | Synthis Therapeutics, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3980423-A1 | 5H-PYRROLO[3,2-D]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3980080-A1 | IMMUNOMODULATOR ANTIBODY DRUG CONJUGATES AND USES THEREOF | Sutro Biopharma, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| EP-3962951-A1 | ANTI-BCMA ANTIBODY CONJUGATES | Sutro Biopharma, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255975-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR MT1-MMP | MMEL1, MMP3, TIMP3 | LMNA 1332/4885SMN1; SMN2 2304/4885HPGD 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.